全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:... Cristina Nieto-Jiménez , Atanasio Pandiella , Arnoud J Templeton
来源:[J].Molecular Cancer(IF 5.134), 2017, Vol.16 (1)
摘要:Expression of high levels of immune cells including neutrophils has been associated with detrimental outcome in several solid tumors and new strategies to decrease their presence and activity are currently under clinical development. Here, we review some of the relevant literatur...
作者:Atanasio Pandiella , Eitan Amir
来源:[J].Molecular Diagnosis & Therapy(IF 1.692), 2017, Vol.21 (3), pp.337-343
摘要:Companion diagnostics permit the selection of patients likely to respond to targeted anticancer drugs; however, it is unclear if the drug development process differs between drugs developed with or without companion diagnostics. Identification of differences in study design could...
作者:... Laura Díaz-Gil , Alberto Ocaña , Atanasio Pandiella
来源:[J].Cancer Letters(IF 4.258), 2020, Vol.470, pp.161-169
摘要:Abstract(#br)Small molecule inhibitors (TKIs) of HER2 have demonstrated clinical benefit in HER2-positive breast tumors. One of them, lapatinib, is used once advanced tumors become refractory to the HER2 antibody trastuzumab. Another one, neratinib, has shown benefit in high-risk...
作者:Alberto Ocaña , Eitan Amir , Atanasio Pandiella
来源:[J].Breast Cancer Research(IF 5.872), 2020, Vol.22 (25), pp.646-674
摘要:Abstract(#br)Background(#br)There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1). Methods(#br)Through a literature-based ap...
作者:... Joaquín Arribas , Alberto Ocaña , Atanasio Pandiella
来源:[J].Cancer Letters(IF 4.258), 2019, Vol.453, pp.34-44
摘要:Abstract(#br)The appearance of resistance to the anti-HER2 targeted drug trastuzumab constitutes, nowadays, an important challenge in the oncology clinic. To fight such resistance, we searched for potential vulnerabilities in cells resistant to that drug. To that end, we used cel...
作者:Atanasio Pandiella , Eitan Amir
来源:[J].Cancer Treatment Reviews(IF 6.024), 2019, Vol.77, pp.11-19
摘要:Abstract(#br)Introduction(#br)Identification of membrane proteins expressed exclusively on tumor cells is a goal for cancer drug development. The receptor tyrosine kinase-like orphan receptor type 1 and 2 (ROR1/2), are type-I transmembrane proteins expressed in cancer but no...
作者:... Sara García-Alonso , Eitan Amir , Atanasio Pandiella
来源:[J].Trends in Pharmacological Sciences(IF 9.25), 2018
摘要:The failure rate of development of new drugs in oncology is high, with up to 95% of drugs tested in Phase I not reaching the market. Causes behind this high failure rate are discussed here, and solutions to increase the success in the development of antitumor drugs are suggested.
作者:Atanasio Pandiella , Balázs Győrffy
来源:[J].PLoS ONE(IF 3.73), 2017, Vol.12 (5)
摘要:Most patients with early stage triple negative breast cancer (TNBC) receive adjuvant chemotherapy. Activation of the immune system is associated with tumor response and may help identify TNBC with favorable outcome.Gene expression data were obtained from the GEO Dataset GDS2250/G...
作者:... Michael W Deininger , Atanasio Pandiella , Ricardo Sánchez Prieto
来源:[J].PLoS ONE(IF 3.73), 2017, Vol.4 (7)
摘要:Resistance to Imatinib Mesylate (IM) is a major problem in Chronic Myelogenous Leukaemia management. Most of the studies about resistance have focused on point mutations on BCR/ABL. However, other types of resistance that do not imply mutations in BCR/ABL have been also described...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×